The primary goals of this grant for a Southwest Oncology Group research program within the Columbia Presbyterian Cancer Center are: (1) To support the infrastructure for an integrated multimodality SWOG clinical research program. 2) To increase participation of the Columbia Presbyterian Cancer Center (CPCC) investigators in the design, conduct and analysis of SWOG studies. A particular strength of the institution is its expertise in breast and prostate cancer, marrow transplant and gene therapy as well as epidemiology, carcinogenesis and molecular epidemiology. 3) For minority cancer SWOG patients in upper Manhattan, to identify and ameliorate perceived and actual impediments to participation in clinical cancer trials. This application represents collaboration between investigators in the Departments of Medicine, Surgery, Neurosurgery, Gynecology, Radiation Oncology, Urology, and Epidemiology within the Columbia Presbyterian Medical Center (CPMC). There are about 3000 new cancer patients each year at CPMC. Thus there are sufficient numbers of patients for SWOG clinical trials. The cancer patient population at CPMC comprises 10% Afro-American and 20% Hispanic. Superb laboratory skills in cellular and molecular biology exist within the Cancer Center and the University. Many investigators have been participants in SWOG studies but in an uncoordinated manner. The current grant will allow Columbia to provide an infrastructure to coordinate and support their research efforts, provide some data management support, but most importantly, fund travel to SWOG meetings for increasing the participation of physician and nurse investigators and for training of data managers in SWOG training seminars.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA068183-03
Application #
2008945
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1995-05-01
Project End
1997-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 77 publications